Guided Therapeutics, Inc.
GTHP
$0.25
$0.0525.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 590.00K | 60.00K | 117.00K | -- | 1.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 590.00K | 60.00K | 117.00K | -- | 1.00K |
| Cost of Revenue | 132.00K | 25.00K | 38.00K | -- | 3.00K |
| Gross Profit | 458.00K | 35.00K | 79.00K | -- | -2.00K |
| SG&A Expenses | 1.31M | 384.00K | 709.00K | 340.00K | 392.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.57M | 545.00K | 880.00K | 414.00K | 535.00K |
| Operating Income | -980.40K | -485.00K | -763.00K | -414.00K | -534.00K |
| Income Before Tax | -1.22M | -742.00K | -811.00K | -427.00K | -652.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.22M | -742.00K | -811.00K | -427.00K | -652.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.22M | -742.00K | -811.00K | -427.00K | -652.00K |
| EBIT | -980.40K | -485.00K | -763.00K | -414.00K | -534.00K |
| EBITDA | -977.40K | -483.00K | -760.00K | -412.00K | -532.00K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 84.60M | 81.69M | 78.84M | 68.29M | 61.57M |
| Average Diluted Shares Outstanding | 84.60M | 81.69M | 78.84M | 68.29M | 61.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |